Remove 2010 Remove Marketing Remove Public Use
article thumbnail

Battle of the spiritual and holistic therapists over ‘Archangel Alchemy’ trade mark

The IPKat

Stone had began marketing an online ‘metaphysical education’ course under the brand ‘ARCHANGEL ALCHEMY’ in or around July 2019, with the course first starting on 23 September 2019 and running until 21 September 2020.

article thumbnail

Intellectual Property Tools for Protecting Fashion Goods

LexBlog IP

The next time you would like to protect a great innovative design you expect will be a big hit on the market, you should consider obtaining a design patent. 2010) (citing Lee v. 2010) (quoting Payless Shoesource, Inc. Scenario 2: Protecting Novel Designs by Patent. ” [8]. ” [8]. 2d 1214, 1217 (S.D. Just Toys, Inc. ,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Intellectual Property Tools for Protecting Fashion Goods

Above the Fold

The next time you would like to protect a great innovative design you expect will be a big hit on the market, you should consider obtaining a design patent. 2010) (citing Lee v. 2010) (quoting Payless Shoesource, Inc. Scenario 2: Protecting Novel Designs by Patent. The application process for a design patent is simple.

article thumbnail

Deliberating Colonial Policies to Understand the Causes behind Tribal Revolts in the Chota Nagpur Plateau – Part I

IP and Legal Filings

The eminent domain is the power of the sovereign to acquire property of an individual for public use without the necessity of his consent. viii] Amar Nath Jha, “Locating The Ancient History Of Santal Parganas” 70 Proceedings of the Indian History Congress 187 (2009-2010). This power is based on sovereignty of the State.

article thumbnail

Biosimilars 2020 Year in Review

Fish & Richardson Trademark & Copyright Thoughts

At the same time, market uptake of biosimilars in the United States continued to increase, suggesting that there is room for expansion of biosimilars in the U.S. In addition, fewer new biosimilars entered the market this past year, with five biosimilar launches in 2020 as compared to seven in 2019. Yet biosimilars of anti-TNF?